Lumito has CE-marked its first product SCIZYS
Lumito has CE-marked its first product, SCIZYS. This is an important milestone for Lumito and means that sales for the histopathological research market can begin. SCIZYS S1 now fulfils all the relevant provisions of the EC Machinery Directive 2006/42/EC. The internal work required to be able to CE mark the product after receiving the final […]
Warrants of series TO5 were subscribed to approximately 79.2 percent and Lumito receives approximately SEK 20.4 million
Lumito AB (publ) ("Lumito" or the "Company") today announces the outcome of the exercise of warrants of series TO5, which were issued in connection to an issue and loan financing during the fourth quarter of 2023. In total, 27,253,935 warrants were exercised, corresponding to approximately 79.2 percent of the total number of outstanding warrants, for […]
The last day of trading with the warrants of series TO5 in Lumito AB is today, June 4, 2024
Today, June 4, 2024, is the last day of trading with the warrants of series TO5 in Lumito AB (publ) (“Lumito” or the “Company”). The exercise period for the warrants runs up to and including June 10, 2024. Each warrant of series TO5 gives the owner the right to subscribe for one (1) new share […]
The subscription price for exercise of warrants of series TO5 in Lumito AB is set to SEK 0.75 and the subscription period commences today May 27
Lumito AB (publ) ("Lumito" or the "Company") issued warrants of series TO5 in connection to an issue and loan financing during the fourth quarter of 2023. Each warrant gives the right to subscribe for one (1) new share in the Company. The subscription price for the warrants has been set to 70 percent of the […]
Lumito AB publishes Quarterly Report 1, 2024
Financial overview of the first quarter January 1 to March 31, 2024 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -7 113 (-7 245). Earnings per share before and after dilution amounted to SEK -0,03 (-0,04). Cash flow from operating activities after changes in working capital amounted to TSEK -7 180 […]
Lumito AB publishes Quarterly Report 4, 2023
Financial overviewFourth quarterOctober 1 – December 31, 2023 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -5 777 (-6 612). Earnings per share before and after dilution amounted to SEK -0,03 (-0,03). Cash flow from operating activities after changes in working capital amounted to TSEK -5 480 (-5 153). Full […]
Conversion of paid subscribed units (BTU) and first day of trading with warrants of series TO5 and TO6
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Lumitos issue of warrants is fully subscribed multiple times
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Last day of trading with unit rights in Lumito
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
The subscription period in Lumito’s issue of warrants begins today
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
